We received some great feedback from some of the people involved in research we based a previous post on.
“I like your concise and easy to read summary. I think my main comment is that our emphasis is slightly different. Overall, our systematic review was not specifically on the effect of atypical antipsychotics for the treatment of ADHD. It was focused primarily on the effect of atypical antipsychotics in the group of disorders called disruptive behaviour disorders which include conduct disorder, oppositional defiant disorder and disruptive behaviour not otherwise specified. However ADHD coexist in 5 out of the 8 studies we reviewed. This idea was explored specifically in one of the article (Armenteros 2007) that looked at augmentation of treatment of ADHD with risperidone specifically on treatment of aggression in ADHD kids. I think that in the future, there may be potentially more studies looking at the use of atypical antipsychotics for ADHD as it is a novel area of research. I also read with interest an article from the Vancouver Star from Jan 2013 on your blog and that it was related to an article in the Journal of Canadian Psychiatry and it also seemed related to our systematic review. I will check it out further.” Jik Loy on behalf of Sally Merry, Karolina Stasiak and Sarah Elisabeth Hetrick
On another note, new post on Concerta coming soon!